Table 1.
Baseline Demographics by Treatment Arm
| All subjects N (%) or median (IQR) |
High Dose N (%) or median (IQR) |
Low Dose N (%) or median (IQR) |
Controls N (%) or median (IQR) |
|
|---|---|---|---|---|
| Total | 37 randomized | 17 | 20 | 154 |
| Females | 12 (32%) | 4 (24%) | 8 (40%) | 47 (31%) |
|
Age (mo) at Starting OIT or observation (controls) |
||||
| 9–12 | 9 (24%)† | 4 (24%) | 5 (25%) | 15 (10%) |
| 13–24 | 17 (46%) | 9 (53%) | 8 (40%) | 67 (44%) |
| 25–36 | 11 (30%) | 4 (24%) | 7 (35%) | 72 (47%) |
| Race | ||||
| White | 33 (89%)†† | 16 (94%) | 17 (85%) | 92 (60%) |
| Black | 3 (8%) | 0 | 3 (15%) | 24 (16%) |
| Other | 1 (3%) | 1 (6%) | 0 | 38 (25%)* |
| History of: | ||||
| Asthma/recurrent wheeze | 10 (27%)** | 6 (35%) | 4 (20%) | 20 (13%) |
| Atopic Dermatitis | 26 (70%) | 14 (82%) | 12 (60%) | 130 (84%) |
| Allergic Rhinitis | 8 (22%) | 4 (24%) | 4 (20%) | 51 (33%) |
| Peanut SPT (mm) | 11.5 (8, 16.5) | 12.5 (8, 17.5) | 10.5 (8, 15.3) | n/a |
| Peanut IgE (kUA/L) | 14.4 (3.4, 48.6) | 12.3 (3.2, 61.5) | 22.4 (5.4, 43.4) | 21.9 (6.9, 73) |
|
Cumulative eliciting dose, entry OFC (mg) |
21 (21, 171) | 21 (21, 221) | 21 (9.8, 152) | n/a |
| Peanut IgG4 (mcg/mL) | 0.5 (0.2, 1.0) | 0.5 (0.2, 1.0) | 0.5 (0.1, 1.1) | n/a |
†
p=0.03 vs. controls
††
p=0.0005 vs. controls
*
p=0.001 vs. all E-OIT
**
p=0.04 vs. controls